Chats Collaborations Competitions Conferences Lectures Programs    
About Us
- Home
- Overview
- Mission & Vision
- Executive Board
- Advisory Board
 
Involvement
- Events
- Membership
- Sponsorship
- Contact Us
 
Search

Sponsorship

About | Benefits | Levels | Partners | Registration

About

The YBPS invites people, universities, companies, organizations, and governments with an interest in supporting the growth and expansion of the local and global biotechnology and pharmaceutical networks to consider sponsoring the YBPS. With the funds obtained through sponsorship, the YBPS plans activities that serve a vital function: To bring together the various people and groups involved in the biotechnology and pharmaceutical sectors and to provide these people and groups with biotechnology- and pharmaceutical-related educational and networking opportunities.

Benefits

The YBPS offers the following incentives to potential partners in an effort to establish a mutually-beneficial working relationship between partners and the organization.

  • The opportunity to partake in our chats and lectures.
  • The opportunity to judge and network with participating teams of students and post-doctoral fellows during the Pharmaceutical Case Competition and the Y50K Biotechnology Entrepreneurial Competition.
  • The opportunity to speak at and to host a booth at the Yale-New Haven Biotechnology & Pharmaceutical Symposium and Career Fair.
  • The opportunity to participate in a variety of our programs, including the Business of Biotechnology Program, the Consulting Program, the Employment Program, the Equity Research Program, and the Technology Licensing Program.
  • The opportunity to advertise recent news, upcoming events, and employment opportunities on our website and in our weekly YBPS Notes email, which is distributed to our 1200+ members.
  • The opportunity to access our growing resume database (coming soon).

Levels

The YBPS offers five levels of sponsorship so that each potential partner, with its own unique needs, resources, and circumstances, is able to provide a level of support with which it is comfortable.

  • Diamond Partners: $7500
  • Platinum Partners: $5000
  • Gold Partners: $2500
  • Silver Partners: $1000
  • Bronze Partners: $500
  • As a university-based organization, all of the funds raised through sponsorship go directly to supporting the YBPS in its effort to achieve its mission and vision.
  • The sponsorship period begins on the date in which the group is added to the Partners section on the Sponsorship page of the YBPS website and lasts one year.

Partners

We thank the following partners for their generous sponsorship support.

 

Diamond

Wiggin And Dana

Wiggin and Dana provides first-class legal counsel to an international client base of major corporations and institutions, as well as to private businesses, entrepreneurs, individuals, and families. From offices in New Haven, Stamford, and Hartford, Connecticut, Philadelphia, Pennsylvania, and New York City, the firm serves clients located in the Northeast, as well as throughout the United States, Canada, Europe, Latin America, and Asia. The firm acts as general or special counsel for publicly-traded corporations, banks, accounting, architectural engineering and securities firms, public utilities, insurance companies, family-owned businesses, new technology companies and start-ups, hospitals, nursing homes, healthcare providers, universities, colleges and schools, and individuals.
 
 

 

Platinum

Boehringer-Ingelheim, headquartered in Ingelheim, Germany, currently has nearly 36,000 employees and 144 affiliated companies spread around the globe. They are a research-driven group of companies dedicated to researching, developing, manufacturing, and marketing pharmaceuticals that improve health and quality of life. Their business consists of prescription medicines, consumer healthcare, and animal health.
 

 

Bristol-Myers Squibb is a leading provider of medicines to fight cancer, cardiovascular and metabolic disorders, infectious diseases, and serious mental illness. They also make and sell nutritional products, ostomy and advanced wound-care products, and cardiovascular imaging products. In their world-class research and development facilities -- located in New Jersey, Connecticut, and elsewhere around the globe – they are looking for new and better treatments for cancer, rheumatoid arthritis, hepatitis B, diabetes, and other serious illnesses and conditions. Augmenting their internal research and development capabilities, Bristol-Myers Squibb has an extraordinary history of successful partnerships to develop and deliver important new medicines to people who need them worldwide.
 

 

Roche is a leading healthcare company with a uniquely broad spectrum of innovative solutions. For more than 100 years, the company has been active in the discovery, development, manufacture, and marketing of novel healthcare solutions. Their products and services address prevention, diagnosis, and treatment of diseases, thus enhancing well-being and quality of life.
 

 

Gold

Chromocell is located in the Commercialization Center for Innovative Technologies in North Brunswick, New Jersey. The facility is situated in the biotechnology corridor of New Jersey and is surrounded by numerous life sciences companies, as well as leading universities and medical research institutions. Using their proprietary Chromovert technology, they can rapidly create a variety of cell-based products that will obviate some of the most time-consuming and labor-intensive steps of the drug discovery process. Although Chromovert can aid the research efforts of companies or academic laboratories of all sizes, it is in the context of large-scale drug screening and development where its outstanding value can be fully appreciated.
 

 

Merck is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures, and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service.
 

 

Vion Pharmaceuticals is developing novel agents for the treatment of cancer. They have two small molecule anticancer compounds under evaluation in human clinical trials. Their product, Cloretazine®, is currently being studied in a Phase Three trial for relapsed acute myelogenous leukemia (AML) and a pivotal Phase Two trial in elderly de novo poor-risk AML. In addition, trials of Cloretazine® are underway in pediatric brain tumors, small cell lung cancer, and advanced hematologic malignancies. Their second clinical-stage product, Triapine®, is being evaluated in several trials sponsored by the National Cancer Institute. Additional small molecule anticancer compounds are under development in preclinical studies.
 

 

The Yale University Office of Cooperative Research (OCR) was founded in 1982 and charged with extending and expanding Yale University's interaction with the private sector. The duties of the OCR include oversight for patenting and licensing activities, university inventions, and contractual relationships between faculty and industry. OCR staff work with Yale researchers to identify inventions that may ultimately become commercial products and services useful to the public. OCR staff also engage in industrial partnerships to license Yale inventions. An important goal for the Yale OCR is to identify new ideas, cultivate venture funding for them, and facilitate their development into companies that become part of the New Haven economy.
 

 

Silver

Achillion Pharmaceuticals is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company’s proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion Pharmaceuticals is focused on solutions for the most challenging problems in infectious disease, including HIV/AIDS, hepatitis, and resistant bacterial infections.
 

 

Connecticut United for Research Excellence (CURE) is the educational and business support network organization for bioscience in Connecticut, with over 100 members. Its mission is to build networks and critical mass for the industry within the state, to keep Connecticut competitive in bioscience, and to tell the Connecticut bioscience story.
 

 

CuraGen is a biopharmaceutical company dedicated to improving the lives of patients by developing novel pharmaceutical products that address unmet medical needs. CuraGen's deep understanding of the human genome has enabled them to gain greater insight into the molecular basis of disease. The company's therapeutics are based on novel drug targets that are believed to play a role in proven mechanisms underlying disease. CuraGen has translated this understanding into a pipeline of protein, antibody, and small molecule drugs in the areas of oncology, inflammatory diseases, and diabetes. The company's strategy remains focused on advancing its pipeline of promising therapeutics through clinical and preclinical development.
 

 

OrbiMed Advisors is a preeminent asset management firm focused on the global health sciences industry, with over $5 billion in assets under management across a family of venture capital funds, hedge funds, and other investment vehicles. OrbiMed's investment advisory activities were founded in 1989 by Samuel D. Isaly with a vision to invest across the spectrum of healthcare companies: from small privately-held firms to large multinational companies.

OrbiMed's investment team includes over 20 experienced professionals with backgrounds in science, medicine, finance, and law. These professionals work together in a collaborative, team-oriented approach. OrbiMed seeks to be the capital provider of choice for life sciences companies pursuing growth and new opportunities. Where appropriate, particularly within its venture capital activities, OrbiMed supports its invested companies in achieving strategic, financial, and operational objectives via participation at the Board of Directors level. OrbiMed professionals currently serve on the Board of Directors of many different life sciences companies.
 

 

Bronze

 

Apredica's mission is to provide the benefits of outsourced early ADME-Tox analysis with the same speed and service quality provided by an in-house service department. They combine the flexibility, expertise, and low-cost of outsourcing with the speed and scientist-to-scientist communications of insourcing.
 

 

 
 

 

Twenty-first century research in the biological and biomedical sciences is fast-paced, exciting, and interdisciplinary. Training students to excel in this research environment is the singular goal of the Combined Program in the Biological and Biomedical Sciences (BBS). To meet this challenge, BBS has been designed as a novel and continually evolving graduate educational system. Departmental boundaries have been reduced to provide students with access to rigorous training throughout the entire Yale University campus. Courses, seminars, departmental retreats, and most importantly, more than 280 faculty labs are all open to students in the BBS Program. A graduate degree from Yale will represent a thorough, interdisciplinary, cutting-edge education that will open doors in academia, industry, business, and the numerous other career paths that the graduates pursue.
 

 

Integrated DNA Technologies (IDT) is the largest supplier of custom nucleic acids in the U.S. Serving the areas of academic research, biotechnology, and pharmaceutical development, IDT’s primary business is the manufacturing of DNA and RNA oligonucleotides (oligos) for research applications.

In addition, IDT is a leading developer of novel technologies that improve the efficacy of biomedical research and that raise the standard and availability of the bioinformatics tools needed to support these research activities.

Supporting IDT’s mission to advance research in nucleic acid-based technologies, the staff at IDT combine expertise in synthetic chemistry, biophysics, molecular biology, bioinformatics, and engineering. Basic product offerings include DNA oligos, RNA oligos, and over a hundred chemical modifications, ranging from short single-stranded oligos to 10,000 base pair synthetic genes. IDT products support DNA sequencing, DNA amplification, SNP detection, microarray analysis, expression profiling, gene quantification, and functional genomics. IDT scientists have developed novel methods for gene silencing and offer specialized RNAi, ddRNAi, and antisense reagents.

For almost twenty years, IDT’s development has been guided by its uncompromising approach to quality, its belief in the value of good service, and its determination to minimize cost. Currently, over 67,000 customers worldwide turn to IDT to fulfill their oligo requirements.
 

 

Metrum Research Group is a global leader in the development and application of innovative mathematical modeling and simulation methods in clinical pharmacology and related biomedical sciences. Metrum Research Group provides quality research and strategic consulting services to the pharma/biotech sectors and non-profit research centers. Metrum Research Group's research initiatives include the implementation of open source software and high-performance computing technologies to facilitate quantitative problem-solving and rational decision-making and enhancing knowledge-building in biomedical R&D through quantitative modeling and simulation.
 

 

Registration

To become a partner with the Yale Biotechnology & Pharmaceutical Society, please contact our President with your interest.

 

 

Yale Biotechnology & Pharmaceutical Society
Copyright © 2005 - Yale Biotechnology & Pharmaceutical Society
Last Updated: September 17, 2007
www.yale.edu/ybps